By Colin Kellaher
Incyte unveiled positive top-line results from a pair of late-stage studies of its povorcitinib drug candidate in the chronic, inflammatory skin condition hidradenitis suppurativa.
Incyte on Monday said both Phase 3 studies met their primary endpoint at both tested doses, showing statistically significant reductions in total abscess and inflammatory nodule count.
The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to irreversible tissue destruction and scarring.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2025 07:21 ET (11:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。